Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE·NASDAQ

$84.19

+3.0%
HealthcareBiotechnology

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$5.21B
EPS-4.2200
P/E Ratio-19.95
Earnings Date08/10/2026

apge

Property, Plant, and Equipment (Net)

Last Annual Value

14.38M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. Competitors Analysis of Property, Plant, and Equipment (Net)

APGE · NASDAQ
CompanyProperty, Plant, and Equipment (Net)
CAGR 3Y
CAGR 5Y
CAGR 10Y
14.38M
77.0%N/AN/A 
402.00M
28.5%23.0%N/A
267.00M
-2.8%8.7%31.7%
19.57M
241.6%150.1%N/A
CELC logo
Celcuity Inc.
NASDAQ:CELC
550.00K
-4.4%-0.2%14.3%
2.25M
2.4%5.2%N/A
2.38M
78.3%39.2%36.9%
Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. Fair Value Envelope

APGE · NASDAQ

Our analysis suggests that APGE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $84.19, this represents a potential HIDDEN relative to our calculated worth for Apogee Therapeutics, Inc..

Intrinsic Value
Current Price: $84.19